Merck & Co. Inc. (MRK)
| Bid | 93.67 |
| Market Cap | 236.64B |
| Revenue (ttm) | 63.79B |
| Net Income (ttm) | 17.02B |
| EPS (ttm) | 6.74 |
| PE Ratio (ttm) | 13.9 |
| Forward PE | 10.49 |
| Analyst | Buy |
| Ask | 93.69 |
| Volume | 9,120,511 |
| Avg. Volume (20D) | 14,225,698 |
| Open | 94.58 |
| Previous Close | 94.73 |
| Day's Range | 93.10 - 94.68 |
| 52-Week Range | 81.04 - 134.63 |
| Beta | 0.36 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops...
Analyst Forecast
According to 14 analyst ratings, the average rating for MRK stock is "Buy." The 12-month stock price forecast is $111, which is an increase of 18.49% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
6 hours ago · accessnewswire.com
April 14, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against MRKNEW YORK, NY / ACCESS Newswire / March 21, 2025 / If you suffered a loss on your Merck & Co., Inc. (NYSE:MRK) investment and want to learn about a potential recovery under the federal securities laws,...
